BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20603605)

  • 1. ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.
    Appaiah H; Bhat-Nakshatri P; Mehta R; Thorat M; Badve S; Nakshatri H
    Cancer Biol Ther; 2010 Sep; 10(6):600-14. PubMed ID: 20603605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers.
    Brody JR; Witkiewicz AK
    Cancer Biol Ther; 2010 Sep; 10(6):615-6. PubMed ID: 20686361
    [No Abstract]   [Full Text] [Related]  

  • 3. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
    Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
    Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.
    Rhodes LV; Bratton MR; Zhu Y; Tilghman SL; Muir SE; Salvo VA; Tate CR; Elliott S; Nephew KP; Collins-Burow BM; Burow ME
    Exp Cell Res; 2011 Nov; 317(18):2573-81. PubMed ID: 21906588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells.
    Kang H; Mansel RE; Jiang WG
    Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.
    Ramos EA; Grochoski M; Braun-Prado K; Seniski GG; Cavalli IJ; Ribeiro EM; Camargo AA; Costa FF; Klassen G
    PLoS One; 2011; 6(12):e29461. PubMed ID: 22220212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231.
    Morini M; Astigiano S; Gitton Y; Emionite L; Mirisola V; Levi G; Barbieri O
    BMC Cancer; 2010 Nov; 10():649. PubMed ID: 21108812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis.
    Sun Y; Mao X; Fan C; Liu C; Guo A; Guan S; Jin Q; Li B; Yao F; Jin F
    Tumour Biol; 2014 Aug; 35(8):7765-73. PubMed ID: 24810923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells.
    Mohammadzadeh R; Saeid Harouyan M; Ale Taha SM
    Tumour Biol; 2017 Mar; 39(3):1010428317695925. PubMed ID: 28349828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
    Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
    Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12.
    Douglass S; Meeson AP; Overbeck-Zubrzycka D; Brain JG; Bennett MR; Lamb CA; Lennard TW; Browell D; Ali S; Kirby JA
    J Pathol; 2014 Sep; 234(1):74-85. PubMed ID: 24870556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms.
    Rahimi M; George J; Tang C
    Int J Cancer; 2010 Apr; 126(8):1850-1860. PubMed ID: 19830694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEA3 activates CXCR4 transcription in MDA-MB-231 and MCF7 breast cancer cells.
    Gu S; Chen L; Hong Q; Yan T; Zhuang Z; Wang Q; Jin W; Zhu H; Wu J
    Acta Biochim Biophys Sin (Shanghai); 2011 Oct; 43(10):771-8. PubMed ID: 21831961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
    Chang XZ; Li DQ; Hou YF; Wu J; Lu JS; Di GH; Jin W; Ou ZL; Shen ZZ; Shao ZM
    Breast Cancer Res; 2007; 9(6):R76. PubMed ID: 17980029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invading basement membrane matrix is sufficient for MDA-MB-231 breast cancer cells to develop a stable in vivo metastatic phenotype.
    Abdelkarim M; Vintonenko N; Starzec A; Robles A; Aubert J; Martin ML; Mourah S; Podgorniak MP; Rodrigues-Ferreira S; Nahmias C; Couraud PO; Doliger C; Sainte-Catherine O; Peyri N; Chen L; Mariau J; Etienne M; Perret GY; Crepin M; Poyet JL; Khatib AM; Di Benedetto M
    PLoS One; 2011; 6(8):e23334. PubMed ID: 21858074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemokine receptor CXCR4 gene silencing with shRNA inhibits breast cancer metastasis to the lung in nude mice].
    Zhang MX; Han N; Yu SY; Leng Y
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):325-9. PubMed ID: 18953828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HS3ST2 modulates breast cancer cell invasiveness via MAP kinase- and Tcf4 (Tcf7l2)-dependent regulation of protease and cadherin expression.
    Vijaya Kumar A; Salem Gassar E; Spillmann D; Stock C; Sen YP; Zhang T; Van Kuppevelt TH; Hülsewig C; Koszlowski EO; Pavao MS; Ibrahim SA; Poeter M; Rescher U; Kiesel L; Koduru S; Yip GW; Götte M
    Int J Cancer; 2014 Dec; 135(11):2579-92. PubMed ID: 24752740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways.
    Sobolik T; Su YJ; Wells S; Ayers GD; Cook RS; Richmond A
    Mol Biol Cell; 2014 Mar; 25(5):566-82. PubMed ID: 24403602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
    Cui B; Zhang S; Chen L; Yu J; Widhopf GF; Fecteau JF; Rassenti LZ; Kipps TJ
    Cancer Res; 2013 Jun; 73(12):3649-60. PubMed ID: 23771907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.
    Deol YS; Nasser MW; Yu L; Zou X; Ganju RK
    J Biol Chem; 2011 Dec; 286(52):44845-54. PubMed ID: 22016394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.